Table 2.
S.aureus, N,=128 IE/BSI | Range/MIC90 DAP (mg/l) | Range/MIC90 LNZ (mg/l) | Range/MIC90 SYN (mg/l) | Range/MIC90 TGC (mg/l) | Range/MIC90 VAN (mg/l) | Range/MIC90 TEC (mg/l) | hVISA n/total (%) | VAN, range of MICs in which hVISA were found (mg/l) | TEC, range of MICs in which hVISA were found (mg/l) | hVISA STs | hVISA-MRSA Clone (ST-SCCmec) |
---|---|---|---|---|---|---|---|---|---|---|---|
IE-MSSA | 0.12–1/ 0.5 | 0.5–4/ 2 | 0.12–2/ 1 | 0.12–0.5/ 0.25 | 0.5–2/ 2 | 0.25–2/ 1 | 10/76 (13.1%) | 0.5–1 | 0.25–1 | 8, 30, 45, 121, 7, 12 | |
IE-MRSA | 0.06–1/ 1 | 0.75–2/ 2 | 0.25–2/ 1 | 0.12–0.5/ 0.5 | 0.5–2/ 2 | 0.5–2/ 2 | 7/76 (9.2%) | 1–2 | 1–2 | 8, 228, 247 | 8-IA/IVc (n=2), 228-I (n=3), 247-IA (n=2) |
BSI-MSSA | 0.06–2/ 1 | 0.5–4/ 4 | 0.25–1/ 0.5 | <0.06–1/ 0.25 | 0.5–2/ 2 | 0.25–2/ 2 | 6/52 (11.5%) | 1 | 0.5–1 | 5, 8, 30, 15 | |
BSI-MRSA | 0.06–1/ 1 | 1–4/ 4 | 0.25–1/ 0.5 | <0.06–0.25/ 0.25 | 1–2/ 2 | 0.5–2/ 2 | 2/52 (3.8%) | 2 | 1–2 | 228 | 228-I (n=2) |
DAP, daptomycin; LNZ, linezolid; TGC, tigecycline; SYN, synercid (quinupristin/dalfoprisitin); VAN, vancomycin; TEC, teicoplanin